Deuterated 1,3 Dihydro‑2H‑indole-2-one Derivatives for Treatment of Depression or Anxiety
1Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Road, Atlanta, Georgia 30322, United States.
Abstract:
This patent application discloses a series of l,3-dihydro-2H-indol-2-one derivatives targeting the vasopressin 1b receptor (V1b) or both the V1a and V1b receptors, as represented by Formula I. These vasopressin receptor antagonists exhibit significant therapeutic potential, particularly for the treatment of depression or anxiety, and hold promises for benefiting patients with reduced dosing frequency.
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Anxiolytic Drugs: Benzodiazepines and Buspirone
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Anxiolytic Drugs: Overview
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic...
Antidepressant Drugs: Overview


